Akizawa, Tadao
Tanaka-Amino, Keiko
Otsuka, Tetsuro
Yamaguchi, Yusuke
Funding for this research was provided by:
Astellas Pharma, Inc.
Article History
Received: 3 December 2021
Accepted: 5 April 2022
First Online: 24 April 2022
Declarations
:
: KTA, TO, and YY are employees of Astellas Pharma, Inc. TA reports personal fees from Astellas, Kyowa Kirin, Bayer Yakuhin Ltd., GlaxoSmithKline, JT Pharmaceuticals, Kissei Pharmaceutical Co. Ltd., Chugai Pharmaceutical Co. Ltd, Ono Pharmaceutical Co. Ltd., Fuso Pharmaceutical Industries Ltd., Torii Pharmaceutical Co. Ltd., Nipro Corporation, Otsuka, Sanwa Chemical, and Tanabe-Mitsubishi Co. Ltd.
: All study protocols were approved by relevant institutional review boards and/or ethics committees and were conducted in accordance with the tenets of the Declaration of Helsinki, the International Council for Harmonization guidelines for Good Clinical Practice, and any other applicable local health and regulatory requirements. All patients provided written informed consent before enrollment.